SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...
Alumis Inc., a clinical-stage biopharmaceutical company focused on therapies for immune-mediated diseases, announced that its stockholders approved all proposals necessary for its merger with ACELYRIN ...
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical ...
A would-be psoriasis winner began taking more distinct shape in the competitive oral tyrosine kinase 2 (TYK2) inhibitor space, and shares of Alumis Inc. (NASDAQ:ALMS) closed Jan. 6 at $16.23, up $7.92 ...
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results